[go: up one dir, main page]

ZA924999B - New compositions containing taxane derivatives - Google Patents

New compositions containing taxane derivatives

Info

Publication number
ZA924999B
ZA924999B ZA924999A ZA924999A ZA924999B ZA 924999 B ZA924999 B ZA 924999B ZA 924999 A ZA924999 A ZA 924999A ZA 924999 A ZA924999 A ZA 924999A ZA 924999 B ZA924999 B ZA 924999B
Authority
ZA
South Africa
Prior art keywords
new compositions
compositions containing
taxane derivatives
containing taxane
derivatives
Prior art date
Application number
ZA924999A
Other languages
English (en)
Inventor
Jean-Pierre Bastart
Thierry Dupechez
Jean-Louis Fabre
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9414814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA924999(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA924999B publication Critical patent/ZA924999B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Paints Or Removers (AREA)
ZA924999A 1991-07-08 1992-07-06 New compositions containing taxane derivatives ZA924999B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9108527A FR2678833B1 (fr) 1991-07-08 1991-07-08 Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Publications (1)

Publication Number Publication Date
ZA924999B true ZA924999B (en) 1993-04-28

Family

ID=9414814

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA924999A ZA924999B (en) 1991-07-08 1992-07-06 New compositions containing taxane derivatives

Country Status (28)

Country Link
US (1) US5403858A (fi)
EP (4) EP0522937A1 (fi)
JP (2) JPH06507914A (fi)
KR (1) KR0136722B1 (fi)
AT (2) ATE147992T1 (fi)
CA (2) CA2102778C (fi)
CZ (1) CZ280965B6 (fi)
DE (3) DE69223624T2 (fi)
DK (2) DK0593656T5 (fi)
ES (2) ES2110003T3 (fi)
FI (2) FI111807B (fi)
FR (1) FR2678833B1 (fi)
GE (1) GEP19991517B (fi)
GR (2) GR3022355T3 (fi)
HK (1) HK1006207A1 (fi)
HU (1) HU217839B (fi)
IE (2) IE80461B1 (fi)
MX (2) MX9203959A (fi)
NO (2) NO307206B1 (fi)
PL (1) PL169372B1 (fi)
RU (1) RU2134123C1 (fi)
SE (1) SE0593656E5 (fi)
SG (1) SG80541A1 (fi)
SK (1) SK279946B6 (fi)
TW (2) TW577752B (fi)
WO (2) WO1993000929A1 (fi)
YU (1) YU48913B (fi)
ZA (1) ZA924999B (fi)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB2269319B (en) * 1992-08-03 1997-04-09 Bristol Myers Squibb Co Methods for administration of taxol
ES2119996T3 (es) * 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
WO1995033490A1 (en) * 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
EP0769936A1 (en) * 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CA2240595A1 (en) * 1995-12-21 1997-07-03 Bijan Almassian Taxane composition and method
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
EP0979290A2 (en) 1997-04-28 2000-02-16 Aventis Pharma S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP0998279B1 (en) * 1997-05-30 2002-10-16 Man Woo Han Pharmaceutical injection solution containing taxol
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6388112B1 (en) 1998-10-20 2002-05-14 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
EP1328213B1 (en) 2000-10-16 2005-07-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
PL203300B1 (pl) 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
EP1337273A2 (en) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
KR20020079239A (ko) * 2001-04-14 2002-10-19 이언식 학습기
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20030101058A1 (en) * 2001-11-26 2003-05-29 Kenneth Liou Voice barcode scan device
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
NZ536308A (en) * 2002-05-24 2009-01-31 Angiotech Int Ag Compositions and methods for coating medical implants
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
EP1539043B1 (en) * 2002-09-20 2013-12-18 Innovational Holdings, LLC Expandable medical device with openings for delivery of multiple beneficial agents
WO2004069224A2 (en) 2003-02-03 2004-08-19 Neopharm, Inc. Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
AU2004226327A1 (en) 2003-03-28 2004-10-14 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
CA2536188A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
WO2008026048A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US20080319048A1 (en) * 2007-06-22 2008-12-25 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
AU2011248449B2 (en) 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
PT2753355T (pt) 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
WO2014013903A1 (ja) 2012-07-19 2014-01-23 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
US10238723B2 (en) 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN110845616A (zh) 2014-03-21 2020-02-28 艾伯维公司 抗-egfr抗体及抗体药物偶联物
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
BR112018075644A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
CN111465389B (zh) 2017-09-07 2022-06-21 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
CA3109440A1 (en) 2018-09-05 2020-03-12 Emcure Pharmaceuticals Ltd. Stable ready-to-use carmustine pharmaceutical composition
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
WO1993000928A1 (fr) 1993-01-21
DK0593656T3 (da) 1997-02-10
EP0522937A1 (fr) 1993-01-13
HU9400052D0 (en) 1994-05-30
IE922213A1 (en) 1993-01-13
FI111807B (fi) 2003-09-30
DK0593601T3 (da) 1998-02-09
NO307205B1 (no) 2000-02-28
EP0593656B1 (fr) 1997-01-22
HK1006207A1 (en) 1999-02-12
EP0593656B3 (fr) 2009-10-07
FI111808B (fi) 2003-09-30
PL169372B1 (en) 1996-07-31
NO934609D0 (no) 1993-12-14
DE69217056D1 (de) 1997-03-06
CA2102778C (fr) 2004-04-20
JPH06507913A (ja) 1994-09-08
SE0593656E5 (sv) 2010-11-30
CZ3294A3 (en) 1995-02-15
ATE147992T1 (de) 1997-02-15
WO1993000929A1 (fr) 1993-01-21
FI940074A (fi) 1994-01-07
DE69217056T4 (de) 2009-08-20
JPH06507914A (ja) 1994-09-08
IE922212A1 (en) 1993-01-13
HUT65960A (en) 1994-08-29
NO934610L (no) 1993-12-14
SG80541A1 (en) 2001-05-22
SK279946B6 (sk) 1999-06-11
ES2096091T3 (es) 1997-03-01
GEP19991517B (en) 1999-03-05
DE69217056T3 (de) 2010-04-22
US5403858A (en) 1995-04-04
ES2096091T7 (es) 2010-03-31
FI940073A (fi) 1994-01-07
SE0593656T6 (fi) 2010-11-30
FI940073A0 (fi) 1994-01-07
DK0593656T5 (da) 2010-01-11
GR3025714T3 (en) 1998-03-31
ES2110003T3 (es) 1998-02-01
IE80461B1 (en) 1998-07-29
CA2102777A1 (fr) 1993-01-09
ATE161193T1 (de) 1998-01-15
YU48913B (sh) 2002-11-15
DE69217056T2 (de) 1997-06-05
NO934609L (no) 1993-12-14
AU666859B2 (en) 1996-02-29
NO307206B1 (no) 2000-02-28
TW495362B (en) 2002-07-21
KR0136722B1 (ko) 1998-04-25
FR2678833B1 (fr) 1995-04-07
YU67692A (sh) 1995-12-04
MX9203959A (es) 1993-01-01
AU2278792A (en) 1993-02-11
HU217839B (hu) 2000-04-28
JP2595458B2 (ja) 1997-04-02
SE0593656T3 (fi) 1997-02-03
RU2134123C1 (ru) 1999-08-10
EP0522936A1 (fr) 1993-01-13
EP0593601A1 (fr) 1994-04-27
EP0593601B1 (fr) 1997-12-17
IE80548B1 (en) 1998-09-09
FI940074A0 (fi) 1994-01-07
DE69223624T2 (de) 1998-04-23
MX9203960A (es) 1993-01-01
DE69223624D1 (de) 1998-01-29
NO934610D0 (no) 1993-12-14
CA2102777C (fr) 2004-09-07
EP0593656A1 (fr) 1994-04-27
FR2678833A1 (fr) 1993-01-15
GR3022355T3 (en) 1997-04-30
TW577752B (en) 2004-03-01
CA2102778A1 (fr) 1993-01-09
SK1594A3 (en) 1994-10-05
CZ280965B6 (cs) 1996-05-15

Similar Documents

Publication Publication Date Title
ZA924999B (en) New compositions containing taxane derivatives
DE59009351D1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
GB8820327D0 (en) New compositions of matter
KR880701555A (ko) 소염제 크림 조성물
ATE184009T1 (de) Halichondrine: zytotoxische polyäther-makrolide
IL108316A0 (en) C-10 taxana derivatives and pharmaceutical compositions containing them
NZ184634A (en) N-(i'allyl-2-pyrrolidylmethyl)-2,3-dimethoxy-5-sulphamoyl-benzamide and pharmaceutical compositions
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
NZ183154A (en) 1,3-dihydro-1-dimethylphosphinylalkyl-3-phenylspiro-(isobenzofuran) derivatives and pharmaceutical compositions
JPS5322529A (en) Dihydropyrazine derivative and its preparation
JPS5336546A (en) Stabilized rubber composition
ATE33552T1 (de) Dermatologische praeparate.
JPS5283776A (en) Novel bicyclo 11,3,0 hexadeca-3-ene derivative
NZ185290A (en) 1,6-anhydro- -d-hexopyranose derivatives and pharmaceutical compositions
JPS5298049A (en) Aromatic copolyester composition
JPS5336545A (en) Stabilized rubber composition